Tharimmune Inc., a clinical-stage biotechnology company focused on therapies in immunology and inflammation, has announced the pricing of a registered direct public offering aimed at raising approximately $1.74 million. The offering includes 414,331 shares of Common Stock and 559,910 pre-funded warrants to acquire shares of Common Stock, along with 974,241 warrants to acquire shares of Common Stock at an exercise price of $1.66 per share. The securities are offered at $1.786 per unit, following a Securities Purchase Agreement. A preliminary prospectus supplement and accompanying prospectus have been filed with the U.S. Securities and Exchange Commission $(SEC.UK)$, with a final prospectus supplement to follow. President Street Global, LLC is serving as the exclusive placement agent for the offering, which is expected to close around July 25, 2025, contingent on customary closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.